Taysha Gene Therapies Other Current Assets 2020-2024 | TSHA
Taysha Gene Therapies other current assets from 2020 to 2024. Other current assets can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Taysha Gene Therapies Annual Other Current Assets
(Millions of US $) |
| 2023 |
$2 |
| 2022 |
$ |
| 2021 |
$ |
| 2020 |
$ |
| 2019 |
$ |
Taysha Gene Therapies Quarterly Other Current Assets
(Millions of US $) |
| 2024-06-30 |
$2 |
| 2024-03-31 |
$2 |
| 2023-12-31 |
$2 |
| 2023-09-30 |
$2 |
| 2023-06-30 |
|
| 2023-03-31 |
|
| 2022-12-31 |
|
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.449B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
